Tumor Microenvironment as a Therapeutic Target in Melanoma Treatment

被引:11
作者
Kharouf, Naji [1 ,2 ]
Flanagan, Thomas W. [3 ]
Hassan, Sofie-Yasmin [4 ]
Shalaby, Hosam [5 ]
Khabaz, Marla [6 ]
Hassan, Sarah-Lilly [4 ]
Megahed, Mosaad [7 ]
Haikel, Youssef [1 ,2 ,8 ]
Santourlidis, Simeon [9 ]
Hassan, Mohamed [1 ,2 ,10 ]
机构
[1] Univ Strasbourg, Inst Natl St & Rech Med, Unite Mixte Rech 1121, Biomat & Bioengn, F-67000 Strasbourg, France
[2] Univ Strasbourg, Fac Dent Med, Dept Endodont & Conservat Dent, F-67000 Strasbourg, France
[3] LSU Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA
[4] Heinrich Heine Univ Duesseldorf, Fac Sci, Dept Chem, D-40225 Dusseldorf, Germany
[5] Tulane Univ, Sch Med, Dept Urol, New Orleans, LA 70112 USA
[6] Beta Factory Vet Pharmaceut Ind, Dept Prod, Damascus, Syria
[7] Univ Hosp Aachen, Clin Dermatol, D-52074 Aachen, Germany
[8] Hop Univ Strasbourg, Hop Civil, Pole Med & Chirurg Bucco Dentaire, F-67000 Strasbourg, France
[9] Heinrich Heine Univ Duesseldorf, Inst Transplantat Diagnost & Cell Therapeut, Med Fac, Epigenet Core Lab, D-40225 Dusseldorf, Germany
[10] Tulane Univ, Sch Med, Dept Surg, Res Lab Surg Oncol, New Orleans, LA 70112 USA
关键词
tumor microenvironment; stromal cells; melanoma resistance; targeted therapy; chronic inflammation; CANCER-ASSOCIATED FIBROBLASTS; REGULATORY T-CELLS; TRANSCRIPTION FACTOR; VITAMIN-D; RESISTANCE; INHIBITION; PROMOTE; BRAF; FIBRONECTIN; NEUTROPHILS;
D O I
10.3390/cancers15123147
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary As a solid tumor, melanoma is not only a tumor mass of monolithic tumor cells, but it also contains supporting stroma, extracellular matrix (ECM), and soluble molecules forming the widely recognized tumor microenvironment. The main components of the tumor microenvironment include stromal cells (endothelial cells, fibroblasts, mesenchymal stem cells, and immune cells), ECM, and soluble molecules (chemokines, cytokines, growth factors, and extracellular vesicles). The tumor microenvironment has been suggested to play a central role in tumor progression and treatment resistance. Accumulated evidence indicates that tumor maintenance, progression, and treatment resistance are determined by components of the microenvironment. Thus, targeting the components of the tumor microenvironment may have a therapeutic impact on melanoma treatment. The main topic of this paper deals with the main components of the tumor microenvironment and their impact as therapeutic targets in melanoma treatment. The role of the tumor microenvironment in tumor growth and therapy has recently attracted more attention in research and drug development. The ability of the microenvironment to trigger tumor maintenance, progression, and resistance is the main cause for treatment failure and tumor relapse. Accumulated evidence indicates that the maintenance and progression of tumor cells is determined by components of the microenvironment, which include stromal cells (endothelial cells, fibroblasts, mesenchymal stem cells, and immune cells), extracellular matrix (ECM), and soluble molecules (chemokines, cytokines, growth factors, and extracellular vesicles). As a solid tumor, melanoma is not only a tumor mass of monolithic tumor cells, but it also contains supporting stroma, ECM, and soluble molecules. Melanoma cells are continuously in interaction with the components of the microenvironment. In the present review, we focus on the role of the tumor microenvironment components in the modulation of tumor progression and treatment resistance as well as the impact of the tumor microenvironment as a therapeutic target in melanoma.
引用
收藏
页数:24
相关论文
共 262 条
  • [71] Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis
    Goldinger, Simone M.
    Buder-Bakhaya, Kristina
    Lo, Serigne N.
    Forschner, Andrea
    McKean, Meredith
    Zimmer, Lisa
    Khoo, Chloe
    Dummer, Reinhard
    Eroglu, Zeynep
    Buchbinder, Elizabeth I.
    Ascierto, Paolo A.
    Gutzmer, Ralf
    Rozeman, Elisa A.
    Hoeller, Christoph
    Johnson, Douglas B.
    Gesierich, Anja
    Koelblinger, Peter
    Bennannoune, Naima
    Cohen, Justine, V
    Kaehler, Katharina C.
    Wilson, Melissa A.
    Cebon, Jonathan
    Atkinson, Victoria
    Smith, Jessica L.
    Michielin, Olivier
    Long, Georgina, V
    Hassel, Jessica C.
    Weide, Benjamin
    Haydu, Lauren E.
    Schadendorf, Dirk
    McArthur, Grant
    Ott, Patrick A.
    Blank, Christian
    Robert, Caroline
    Sullivan, Ryan
    Hauschild, Axel
    Carlino, Matteo S.
    Garbe, Claus
    Davies, Michael A.
    Menzies, Alexander M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 162 : 22 - 33
  • [72] Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients
    Goldinger, Simone M.
    Zimmer, Lisa
    Schulz, Carsten
    Ugurel, Selma
    Hoeller, Christoph
    Kaehler, Katharina C.
    Schadendorf, Dirk
    Hassel, Jessica C.
    Becker, Juergen
    Hauschild, Axel
    Dummer, Reinhard
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (02) : 406 - 410
  • [73] Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase
    Gong, Lei
    Cumpian, Amber M.
    Caetano, Mauricio S.
    Ochoa, Cesar E.
    De la Garza, Maria Miguelina
    Lapid, Daniel J.
    Mirabolfathinejad, Seyedeh Golsar
    Dickey, Burton F.
    Zhou, Qinghua
    Moghaddam, Seyed Javad
    [J]. MOLECULAR CANCER, 2013, 12
  • [74] Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles
    Gorabi, Armita Mahdavi
    Ravari, Mehrnaz Sadat
    Sanaei, Mohammad-Javad
    Davaran, Soodabeh
    Kesharwani, Prashant
    Sahebkar, Amirhossein
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113
  • [75] Oncolytic virotherapy: Challenges and solutions
    Goradel, Nasser Hashemi
    Baker, Alexander T.
    Arashkia, Arash
    Ebrahimi, Nasim
    Ghorghanlu, Sajjad
    Negahdari, Babak
    [J]. CURRENT PROBLEMS IN CANCER, 2021, 45 (01)
  • [76] T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells
    Granados, Karol
    Hueser, Laura
    Federico, Aniello
    Sachindra, Sachindra
    Wolff, Gretchen
    Hielscher, Thomas
    Novak, Daniel
    Madrigal-Gamboa, Veronica
    Sun, Qian
    Vierthaler, Marlene
    Larribere, Lionel
    Umansky, Viktor
    Utikal, Jochen
    [J]. BRITISH JOURNAL OF CANCER, 2020, 122 (07) : 1023 - 1036
  • [77] Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
    Greene, Sarah
    Robbins, Yvette
    Mydlarz, Wojciech K.
    Huynh, Angel P.
    Schmitt, Nicole C.
    Friedman, Jay
    Horn, Lucas A.
    Palena, Claudia
    Schlom, Jeffrey
    Maeda, Dean Y.
    Zebala, John A.
    Clavijo, Paul E.
    Allen, Clint
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1420 - 1431
  • [78] Molecular Pathways: Inflammation-Associated Nitric-Oxide Production as a Cancer-Supporting Redox Mechanism and a Potential Therapeutic Target
    Grimm, Elizabeth A.
    Sikora, Andrew G.
    Ekmekcioglu, Suhendan
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (20) : 5557 - 5563
  • [79] Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities
    Grit, Jamie L.
    Pridgeon, Matt G.
    Essenburg, Curt J.
    Wolfrum, Emily
    Madaj, Zachary B.
    Turner, Lisa
    Wulfkuhle, Julia
    Petricoin, Emanuel F.
    Graveel, Carrie R.
    Steensma, Matthew R.
    [J]. GENES, 2020, 11 (03)
  • [80] Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity
    Gujar, Shashi A.
    Marcato, Paola
    Pan, Da
    Lee, Patrick W. K.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2010, 9 (11) : 2924 - 2933